Biological significance of TERT promoter mutation in papillary urothelial neoplasm of low malignant potential

TERT Promoter Mutations Occur Frequently in Urothelial Papilloma and Papillary Urothelial Neoplasm of Low Malignant Potential

(2017) Liang Cheng et al.   EUROPEAN UROLOGY

Telomerase reverse transcriptase (TERT) promoter mutation analysis of benign, malignant and reactive urothelial lesions reveals a subpopulation of inverted papilloma with immortalizing genetic change

(2016) Liang Cheng et al.   HISTOPATHOLOGY

Study of the reproducibility of the 2004 World Health Organization classification of urothelial neoplasms

(2015) Pallavi Sharma et al.   Indian Journal of Pathology and Microbiology

Mutations inTERTpromoter andFGFR3and telomere length in bladder cancer

(2015) Ismail Hosen et al.   INTERNATIONAL JOURNAL OF CANCER

HRAS mutations are frequent in inverted urothelial neoplasms

(2014) Andrew S. McDaniel et al.   HUMAN PATHOLOGY

NRAS Codon 61 Mutation Is Associated with Distant Metastasis in Patients with Follicular Thyroid Carcinoma

(2014) Eun Kyung Jang et al.   THYROID

FGFR3 mutations, but not FGFR3 expression and FGFR3 copy-number variations, are associated with favourable non-muscle invasive bladder cancer

(2014) Yann Neuzillet et al.   VIRCHOWS ARCHIV

Telomerase Reverse Transcriptase Promoter Mutations in Bladder Cancer: High Frequency Across Stages, Detection in Urine, and Lack of Association with Outcome

(2013) Yves Allory et al.   EUROPEAN UROLOGY

Mutations of the TERT promoter are common in basal cell carcinoma and squamous cell carcinoma

(2013) Glynis A Scott et al.   MODERN PATHOLOGY

TERT promoter mutations in bladder cancer affect patient survival and disease recurrence through modification by a common polymorphism

(2013) P. S. Rachakonda et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Frequency of TERT promoter mutations in human cancers

(2013) João Vinagre et al.   Nature Communications

Incidence of fibroblast growth factor receptor 3 gene (FGFR3) A248C, S249C, G372C, and T375C mutations in bladder cancer

(2011) Y. Dodurga et al.   GENETICS AND MOLECULAR RESEARCH

Histologic grading of urothelial papillary neoplasms: impact of combined grading (two-numbered grading system) on reproducibility

(2011) Burçin Tuna et al.   VIRCHOWS ARCHIV

Combined Gene Expression and Genomic Profiling Define Two Intrinsic Molecular Subtypes of Urothelial Carcinoma and Gene Signatures for Molecular Grading and Outcome

(2010) David Lindgren et al.   CANCER RESEARCH

Bladder cancer: translating molecular genetic insights into clinical practice

(2010) Liang Cheng et al.   HUMAN PATHOLOGY

Molecular pathways of urothelial development and bladder tumorigenesis

(2010) Mireia Castillo-Martin et al.   UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS

FGFR3 and TP53 mutation analysis in inverted urothelial papilloma: incidence and etiological considerations

(2009) Sarah Lott et al.   MODERN PATHOLOGY

Molecular pathogenesis of bladder cancer

(2008) Margaret A. Knowles   International Journal of Clinical Oncology